Sonus Pharmaceuticals to Release Fourth Quarter and Full Year 2002 Financial Results and Hold Year End Conference Call on February 4.Business Editors & Health/Medical WritersBIOWIRE2K BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 27, 2003 Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS SNUS Swedish National Union of Students ) today announced that it will release financial results for the fourth quarter and full year 2002 and provide a company update during its year end conference call on February 4, 2003. Access to the conference call can be obtained as follows: Live Broadcast on Tuesday, February 4, 4:30 P.M. EST P.M. also p.m. or p.m. abbr. post meridiem Usage Note: By definition, 12 a.m. : -- Webcast on Sonus web site at www.sonuspharma.com (Investor Relations/Events) Replay Access: -- Telephone replay accessible from February 4, 7:30 P.M. EST for 24 hours at 800/642-1687; Passcode 7683495 -- Webcast archived until February 11 on Sonus web site at www.sonuspharma.com (Investor Relations/Events) About Sonus Pharmaceuticals Sonus Pharmaceuticals, Inc. is a drug reformulation company focusing on the optimization of cancer therapies. The Company's lead product, TOCOSOL(TM) Paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); , is a novel reformulation of paclitaxel, one of the world's most widely used anticancer drugs Anticancer Drugs Definition Anticancer, or antineoplastic, drugs are used to treat malignancies, or cancerous growths. Drug therapy may be used alone, or in combination with other treatments such as surgery or radiation therapy. . Sonus is also developing a number of other potential product candidates utilizing its proprietary TOCOSOL drug delivery technology. The development of therapeutic drugs with TOCOSOL may result in products that have better efficacy, fewer side effects Side effects Effects of a proposed project on other parts of the firm. and more convenient administration. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion